Scipher Medicine’s $82 Million Financing

McDermott Will & Emery represented Scipher Medicine in the transaction.

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, completed its Series C financing. aMoon, an investment fund based in Israel, and Northpond Ventures, a US-based VC fund, led the funding with participation from Echo Health Ventures and existing investors, Khosla Ventures and Alumni Ventures. To date, the company has raised $117 million.

Scipher Medicine will use the proceeds to expand commercial efforts for its patient molecular signature test, PrismRA®, ensuring rheumatoid arthritis patients are prescribed optimal targeted therapy from day one, and data collaborations to discover novel treatment targets based on their large and growing patient clinico-genomic database generated from tested patients.

McDermott Will & Emery represented Scipher Medicine with a team led by Brian Bunn (Picture) and Jacob Kuipers.

Involved fees earner: Brian Bunn – McDermott Will & Emery; Jacob Kuipers – McDermott Will & Emery;

Law Firms: McDermott Will & Emery;

Clients: Scipher Medicine;

Print Friendly, PDF & Email
Martina Bellini

Author: Martina Bellini